Vytrus Biotech raises EUR 600,000 via equity crowdfunding platform
The company has raised just over EUR 600,000 via the platform Capital Cell, which specialises in biomedicine; this amount represents 110% of its original goal of EUR 550,000.
“This investment will be used to increase the industrial growth of the company and potentiate its research lines, as well as to prepare the company to join an alternative stock market, which will allow us to secure the company and maximize the business growth,” Vytrus explains.
Stem cells in beauty
Plant stem cells continue to be an area of great interest for beauty innovators, with the ingredients holding the potential to encourage skin self-defense and repair.
Indeed, CosmeticsDesign’s exclusive interview with the CEO and Co-founder of Vytrus, published last year, covers some of the key points of focus in this high-potential area of research and innovation.
In the interview, Oscar Expósito explained the science behind the use of plant stem cells, known as ‘totipotent plant cells’.
“We take the molecular cocktail from within the dead cell and use it in topical skin care products,” he explained.
“In the cell there are proteins, sugars, various growth factors, and these all work together to help the plant cell defend or repair itself. They perform very well on the skin, with proven benefits like skin whitening, anti-wrinkle or hair growth.”
Expósito noted that the contents of totipotent plant cells offers a very sophisticated cocktail of natural molecules, and said at the time that although it’s early days for the science, he believes this offers an exciting opportunity for applications in skin and hair care.
The continued funding success of Vytrus Biotech suggests there are stakeholders willing to get behind the technology, with its full potential for the beauty industry yet to be discovered.
